About: Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation
Creator	Altmann, Daniel Doolan, Denise Bénéchet, Alexandre Cardone, Marco Puig, Montserrat Rosenberg, Amy Yano, Masahide
topic	covid:755f6a5a9c683ebc4e5b26fd6457b1cc2a3ca5e0#this
Source	Medline; PMC
abstract	The first case of human transmission of SARS-CoV-2 was reported in China in December 2019. A few months later, this viral infection had spread worldwide and became a pandemic. The disease caused by SARS-CoV-2, termed COVID-19, is multifactorial and associated with both specific antiviral as well as inflammatory responses, the extent of which may determine why some individuals are asymptomatic while others develop serious complications. Here we review possible life-threating immune events that can occur during disease progression to uncover key factors behind COVID-19 severity and provide suggestions for interventions with repurposed drugs in well-controlled and randomized clinical trials. These drugs include therapeutics with potential to inhibit SARS-CoV-2 entry into host cells such as serine protease inhibitors of the cellular protease TMPS2 and drugs targeting the renin-angiotensin system; antivirals with potential to block SARS-CoV-2 replication or factors that could boost the antiviral response; monoclonal antibodies targeting pro-inflammatory cytokines that drive the hyperinflammatory response during COVID-19 progression toward the severe stage and therapeutics that could ameliorate the function of the lungs. Furthermore, in order to help make more informed decisions on the timing of the intervention with the drugs listed in this review, we have grouped these therapeutics according to the stage of COVID-19 progression that we considered most appropriate for their mechanism of action.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.3389/fimmu.2020.01131
bibo:pmid	32574265
has license	cc-by
sha1sum (hex)	755f6a5a9c683ebc4e5b26fd6457b1cc2a3ca5e0
schema:url	https://doi.org/10.3389/fimmu.2020.01131
resource representing a document's title	Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation
has PubMed Central identifier	PMC7272717
has PubMed identifier	32574265
schema:publication	Front Immunol
resource representing a document's body	covid:755f6a5a9c683ebc4e5b26fd6457b1cc2a3ca5e0#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/755f6a5a9c683ebc4e5b26fd6457b1cc2a3ca5e0
is schema:about of	named entity 'function' named entity 'pandemic' named entity 'determine' named entity 'SARS-CoV-2' named entity 'MONOCLONAL ANTIBODIES' named entity 'PANDEMIC' named entity 'DECISIONS' named entity 'TO HELP' named entity 'REPORTED' named entity 'events' named entity 'key' named entity 'drive' named entity 'progression' named entity 'human' named entity 'These' named entity 'monoclonal antibodies' named entity 'SARS-CoV-2' named entity 'protease' named entity 'SARS-CoV-2' named entity 'caused' named entity 'pro-inflammatory cytokines' named entity 'COVID' named entity 'COVID' named entity 'China' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'asymptomatic' named entity 'mechanism of action' named entity 'innate immune' named entity 'spike protein' named entity 'CRS' named entity '8 days' named entity 'SARS-CoV-2' named entity 'lymphocyte count' named entity 'infection' named entity 'infection' named entity 'complement' named entity 'host response' named entity 'lung' named entity 'human body' named entity 'inflammatory diseases' named entity 'COVID-19' named entity 'autocrine loop' named entity 'transmembrane glycoprotein' named entity 'cytokines' named entity 'clinical trials' named entity 'viremia' named entity 'ICU' named entity 'DAMPs' named entity 'COVID' named entity 'CD4' named entity 'COVID-19' named entity 'chemokines' named entity 'lymphopenia' named entity 'cytokine storm' named entity 'COVID' named entity 'apoptotic' named entity 'Wuhan' named entity 'IL-1β' named entity 'cytokine release syndrome' named entity 'neutrophilia' named entity 'CRS' named entity 'high levels' named entity 'immune response' named entity 'computed tomography' named entity 'infection' named entity 'lungs' named entity 'dissection' named entity 'infection' named entity 'CRS' named entity '1, 2' named entity 'type I IFN' named entity 'hyaluronan'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software